Endothelial cell dysfunction: The syndrome in making  by O'Riordan, Edmond et al.
Kidney International, Vol. 67 (2005), pp. 1654–1658
Endothelial cell dysfunction: The syndrome in making
EDMOND O’RIORDAN, JUN CHEN, SERGEY V. BRODSKY, IVA SMIRNOVA, HONG LI, and
MICHAEL S. GOLIGORSKY
Division of Nephrology and Renal Research Institute, Departments of Medicine and Pharmacology, New York Medical College,
Valhalla, New York
Endothelial cell dysfunction: The syndrome in making. En-
dothelial cell dysfunction is emerging as the ultimate cul-
prit for diverse cardiovascular diseases and cardiovascular
complications in patients with chronic renal diseases, yet the
definition of this new syndrome, its pathophysiology and ther-
apy remain poorly defined. Here, we summarize some molecu-
lar mechanisms leading from hyperhomocysteinemia, elevated
asymmetric dimethylarginine (ADMA) and advanced glyca-
tion end products (AGEs)-modified proteins to atherogenic
endothelial phenotype and offer a model of endothelial dys-
function based on the interconnectedness of diverse functions.
TOWARD THE DEFINITION OF ENDOTHELIAL
DYSFUNCTION
The term was first used to describe a defect in the re-
moval of 5-hydroxytryptamine and norepinephrine in the
pulmonary circulation of bleomycin-treated rabbits [1]
and a decrease in angiotensin-converting enzyme (ACE)
and plasminogen activator activities after monocrotaline-
induced lung injury [2]. The modern usage of the term is
associated with the study by Ludmer et al [3], who ob-
served that acetylcholine-induced vasorelaxation is im-
paired, even reversed, early in the course of coronary
atherosclerosis and in recipients of cardiac transplants
[4]. A host of studies by other investigative groups has
confirmed these observations [5–8].
Vascular endothelium, previously viewed as a mere
barrier between intravascular and interstitial compart-
ments, is responsible for the regulation of the hemo-
dynamics, angiogenic vascular remodeling, metabolic,
synthetic, anti-inflammatory, and antithrombogenic pro-
cesses. Based on the diversity of endothelial functions, it
is logical to expect that the definition of the syndrome
of endothelial cell dysfunction (ECD) should be broad
enough to encompass disturbances in the barrier func-
tion of the vascular endothelium; its impaired antithrom-
bogenic properties; perturbed angiogenic competence;
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inappropriate regulation of vascular smooth muscle
tonicity, proliferative capacity and migratory proper-
ties; perturbed synthetic functions and deterrent of
neutrophils and monocytes from diapedesis (Fig. 1). The
phenotype of endothelial cells characterized by these ab-
normalities, expressed to various degrees, is emerging as
a hallmark of several highly prevalent cardiovascular and
renal diseases, including obesity and diabetes, as well as
their complications.
PATHOGENETIC MECHANISMS
Convergence of traditional risk factors, genetic pre-
disposition, local and yet unknown factors acting on
endothelial cells all contribute to development of ECD,
the “ultimate risk of the risk factors” [9]. In addition to
traditional cardiovascular risk factors, a host of comple-
mentary mechanisms responsible for the high prevalence
of cardiovascular complications in patients with chronic
kidney disease has been described. Among the most
important factors are elevated asymmetric dimethyl-
arginine (ADMA) levels, hyperhomocysteinemia, and
protein modification by nonenzymatic advanced
glycation.
Several years ago we elected to study the cellu-
lar and molecular derangements induced by the above
pathogenic stimuli using a nonbiased functional genomic
screening. Toward this end, we performed cDNA mi-
croarray screening of “cardiovascular-relevant” genes
modified by two major contributors to ECD in chronic
renal disease, hyperhomocysteinemia and nitric oxide
synthase (NOS) inhibitor L-arginine analog N-nitro-L-
arginine methyl ester (L-NAME) (to mimic the effect
of ADMA). The results of these studies into some cel-
lular consequences of several cDNA screens have been
published, thus only a brief summary of the essential ob-
servations will be presented [10–16].
Functional analysis and retesting of some mi-
croarray screen findings using reverse transcription-
polymerase chain reaction (RT-PCR) and Western
blotting showed that pathophysiologically relevant con-
centrations of homocysteine result in a profound increase
in 3-hydroxy-3-methylglutaryl coenzymeA (HMG-CoA)
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Fig. 1. An “airport hub” model of endothe-
lial functions. In this model all functions are
intrinsically interconnected and any impair-
ment of one would affect other functions.
Some essential mediators of these functions
are shown in brackets. Pathophysiologic con-
sequences of endothelial dysfunction are de-
picted at the perimeter. HTN is hypertension.
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Fig. 2. Synergistic action of homocysteine-,
asymmetric dimethylarginine (ADMA)-, and
advanced glycation end products (AGEs)-
induced molecular pathways predisposing
to development of endothelial dysfunction.
Abbreviations are: eNOS, endothelial nitric
oxide synthase; NO, nitric oxide; HMG-CoA,
3-hydroxy-3-methylglutaryl coenzymeA;
Hcy, hyperhomocysteinemia.
reductase, synthesis and accumulation of cholesterol in
the endothelial cells, and uncoupling of endothelial NOS
(eNOS) due to oxidative stress—all manifestations of de-
veloping endothelial lipidosis (by analogy with hepatic
lipidosis) [12]. Up-regulation of connexin-43 expression
results in the displacement of this gap junctional protein
from the plasma membrane to the mitochondrion, de-
pletion of myoendothelial gap junctional communication
and the failure of the putative endothelium-derived hy-
perpolarizing factor (EDHF) to relax vascular smooth
muscle cells (VSMCs) [13]. Together with the uncou-
pling of eNOS [10] these findings explain the complex
pathogenesis of vasomotor failure. These and other ab-
normalities and their role in the development of ECD are
schematically illustrated in Figure 2.
The functional sequelae of eNOS inhibition (L-NAME
mimicking elevated ADMA levels) are presented in
Figure 2. Inhibition of nitric oxide synthesis leads not
only to the derangement of endothelium-dependent
vasorelaxation, but has also proatherogenic sequelae,
including enhanced adhesion and transmigration of
monocytes and enhanced platelet aggregation. Up-
regulation of lectin-like receptor for oxidized low-density
lipoprotein (oLDL) (LOX-1), a major receptor for ox-
idized low-density lipoprotein (oxLDL), results in the
increased oxidative stress and lipid accumulation in en-
dothelial cells [15, 16]. Increased synthesis of several
chains of collagen and induction of integrin receptors
participate in the switch of endothelial cells toward the
profibrotic phenotype (unpublished observations). Over-
expression of plasminogen activator inhibitor-1 (PAI-1)
by endothelial cells presented with advanced glycation
end products (AGEs)-modified collagen I is responsible
for the early up-regulation of PAI-1, which is causatively
linked to the inappropriate formation of capillary net-
works during diabetic and/or end-stage renal disease
(ESRD) wound healing and eventual vascular dropout
[11]. There is a remarkable synergy between these risk
factors in inducing oxidative stress, endothelial lipido-
sis, proinflammatory changes, loss of vasorelaxation, as
schematically shown in Figure 2.
It has been debated whether eNOS gene polymor-
phism contributes to ECD. Several potential candi-
date sites have been identified including Glu298Asp,
−786T>C, and intron-4 polymorphisms and incriminat-
ing Asp 298, −786C allele in the promoter and the
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intron-4 with the increased risk of cardiovascular compli-
cations and its association with ESRD [17]. Recent meta-
analysis of 26 studies involving more than 23,000 sub-
jects have demonstrated that homozygosity for Asp298
and intron-4a alleles of eNOS results in a moderately
increased risk of ischemic heart disease [18]. Gene poly-
morphism of other components of the system is beyond
the scope of this review.
CLINICAL SIGNS OF ECD
Manifestations of ECD are many and stem from
the aberrations in individual functions of the endothe-
lium. Figure 1 depicts the relations between perturbed
endothelial functions and the ensuing clinical manifes-
tations. These include hypertension, macro- and mi-
crovasculopathy due to the endothelial lipidosis and
atherogenesis, impaired deterrent of inflammatory cells,
increased vascular permeability manifesting as microal-
buminuria, and impaired angiogenic competence. Each
of these manifestations has been extensively reviewed
elsewhere [19–21].
OXIDATIVE STRESS LEADING TO ECD,
PREMATURE ENDOTHELIAL CELL
SENESCENCE, AND APOPTOSIS
Diverse risk factors and pathologic processes target-
ing the vascular endothelium elicit a default response—
oxidative stress, the now well-established centerpiece of
the response-to-injury hypothesis of atherosclerosis [22,
23]. This uniformly present component of pathologic re-
action modifies endothelial cell functions and leads to cell
demise via premature senescence and apoptosis. We have
recently demonstrated an increased frequency of prema-
turely senescent cells in vivo in aortas of young Zucker
diabetic fat rats with chronic renal insufficiency, com-
pared to lean controls. Nitric oxide production by these
senescent endothelial cells was decreased in association
with the tissue accumulation of nitrotyrosine-modified
proteins, a footprint of oxidative and nitrosative stress
[24, 25]. Development of premature senescence of en-
dothelial cells in vitro could be prevented and reversed
by treatments with the peroxynitrite scavenger, ebselen,
eNOS intermediate Nxhydroxy-L-arginine (NOHA) or
superoxide dismutase (SOD) mimetic Mn, TBAP. Con-
comitant with the reversal of senescence, ebselen and
NOHA each restored nitric oxide production to con-
trol levels. Chronic treatment of Zucker diabetic fat rats
with ebselen not only prevented, but also partially re-
versed ECD [25]. These findings indicate that metabolic
syndrome with chronic renal insufficiency in vivo elicit
premature senescence of the vascular endothelium.
Premature senescence of the vascular endothelium is
hypothesized to be an important contributor to the vas-
culopathy and a consquence of reduced nitric oxide avail-
ability, peroxynitrite, and/or superoxide excess. These
metabolic derangements, together with the oxLDL, tu-
mor necrosis factor-a (TNF-a), and peroxynitrite even-
tually lead to the increased incidence of apoptosis of
endothelial cells, further contributing to the accelerated
atherosclerosis (reviewed in [26]) in the macrovascula-
ture and vascular regression in the microcirculatory bed,
as depicted in Figure 3.
CLINICAL ASSESSMENT
By detecting the syndrome of ECD at preclinical
stages, at present a particularly difficult task, there is
a chance of reversing it. Detecting the syndrome with
certainty through its ominous clinical manifestations
may turn to be too late a stage for any therapy to
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meaningfully halt its progression or reverse it. Thus, the
efficacy of therapy appears to be inversely proportional
to the precision with which the diagnosis can be estab-
lished early. A variety of surrogate markers of ECD have
been proposed, including elevated plasma levels of PAI-
1, tissue plasminogen activator (tPA), and von Wille-
band factor. Stehouwer [27] suggests that “estimates of
different types of ECD may be obtained indirectly by
measuring endothelium-dependent vasodilation, plasma
levels of endothelium-derived regulatory proteins and,
possibly, microalbuminuria.” “Men born in 1914”
plethysmographic study with more than 20 years’ follow-
up provided an early indication of the possible role of
ECD in increased mortality [28]. However, due to the
lack of reliable noninvasive ways of diagnosing ECD,
clinical assessment of the patients remains unsatisfactory.
Plethysmographic or ultrasonographic measurements of
brachial artery responses to flow or acetylcholine have
been advocated as promising markers of ECD, but their
sensitivity in detecting coronary artery disease was found
to be 49% [29]. Several studies have already charac-
terized impaired macrovascular blood flow responses in
ESRD patients [30, 31]. Shamim-Uzzaman et al [32]
have compared brachial artery flow-mediated dilatation
(FMD) with cutaneous microcirculation monitored us-
ing laser Doppler flowmetry in patients with coronary
artery disease and demonstrated no differences in FMD
between coronary artery disease and control subjects;
whereas there were significant abnormalities in the mi-
crocirculatory vasodilatory responses. Our studies of
ESRD patients using laser Doppler flowmetry and imag-
ing showed that several parameters characterizing reac-
tive and thermal hyperemia are impaired in majority of
these patients, regardless of the presence of a known coro-
nary artery disease [33]. This implies that microvascu-
lopathy is highly prevalent in this cohort of patients, even
when there are no clinical manifestations of the coronary
artery disease. We believe that the noninvasive interro-
gation of the cutaneous microvasculature responses to
thermal stimulation may offer a simple screening test for
the presence of systemic ECD [33].
CONCLUSIONS AND FUTURE DIRECTIONS
The phenotype of endothelial cells exposed to sev-
eral highly prevalent risk factors in ESRD, such as
ADMA, hyperhomocysteinemia, and AGEs is defini-
tively proatherogenic. These are cells characterized by
(1) the decreased production of bioavailable nitric ox-
ide, (2) increased adhesiveness for monocytes and poly-
morphonuclear cells, (3) accumulation of cholesterol and
oxLDL, both leading to endothelial lipidosis, (4) defec-
tive transmission of EDHF to the smooth muscle cells,
(5) enhanced expression of profibrotic genes, and (6) a
tendency toward premature senescence and apoptosis.
It is quite possible that individual manifestations of
vascular dysfunction such as inadequate angiogenesis at
ischemic foci, increased adhesion of leukocytes, loss of
antithrombogenic properties, inappropriate proliferation
of VSMCs, and changed patterns of matrix deposition,
each just slightly perturbed, collectively are capable of
triggering early preclinical forms of generalized ECD.
Accordingly, it is important to learn more about nonin-
vasive techniques to assess the functional state of eNOS,
the bioavailability of nitric oxide and expression of other
surrogate markers of ECD in the clinical settings. Our
pharmacopeia needs to be enriched with agents to (1)
correct elevated ADMA levels, (2) elevated homocys-
teine levels, (3) effectively suppress oxidative stress in
the vascular wall, (4) correct increased vascular perme-
ability, (5) improve impaired angiogenesis, and (6) curtail
adhesion and diapedesis of monocytes.
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